Business
Evotec SE to announce first half-year results 2025 on 13 August 2025
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, ...
About this update from Evotec Se
[{"type":"text","content":"HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.","length":268,"tagName":"p"},{"type":"text","content":"The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast details","length":180,"tagName":"p"},{"type":"text","content":"Date: Wednesday, 13 August 2025","length":31,"tagName":"p"},{"type":"text","content":"Time: 2.00 pm CEST (1.00 pm BST, 8.00 am EDT)","length":45,"tagName":"p"},{"type":"text","content":"To join the audio webcast and to access the presentation slides, please register via this link.","length":95,"tagName":"p"},{"type":"text","content":"The on-demand version of the webcast will be available on our website: Financial Publications - Evotec.","length":103,"tagName":"p"},{"type":"text","content":"Conference call details","length":23,"tagName":"p"},{"type":"text","content":"To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.","length":193,"tagName":"p"},{"type":"text","content":"A simultaneous slide presentation for participants dialing in via phone is available under this link .","length":102,"tagName":"p"},{"type":"text","content":"About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.","length":296,"tagName":"p"},{"type":"text","content":"Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.","length":203,"tagName":"p"},{"type":"text","content":"With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone ser...